METHOD FOR DIFFERENTIATED SELECTION OF THERAPY FOR PATIENTS WITH ULCERATIVE COLITIS ON BACKGROUND OF TYPE 2 DIABETES MELLITUS Russian patent published in 2024 - IPC G01N33/48 A61B5/00 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to therapy and gastroenterology, and can be used for the differentiated selection of therapy for patients with inflammatory bowel diseases (IBD) against the background of type 2 diabetes mellitus, taking into account a comprehensive assessment of the composition of the intestinal microbiota. The method includes the determination of representatives of the intestinal microbiota (%) before the start of treatment based on the results of genetic sequencing. Next, the coefficient for predicting the dynamics of diarrheal syndrome is calculated using the formula. If the value of the prognosis coefficient is less than 0.3 conventional units, the first line of therapy is used: mesalazine 3 g/day orally, mesalazine in enemas 2 g/day. If the coefficient value lies in the range from 0.3 to 0.5 conventional units, a second line of therapy is used: sulfasalazine 4 g/day orally, mesalazine in enemas 2 g/day, budesonide rectally 1 mg/kg/day, azathioprine 2 mg/kg/day. If the coefficient value is more than 0.5 conventional units, a third line of therapy is used: sulfasalazine 5 mg/kg/day orally, mesalazine in enemas 5 g/day, budesonide rectally 2 mg/kg/day, azathioprine 2 mg/kg/day, infliximab 5 mg/kg/day, as well as antibacterial therapy-metronidazole 500 mg 2 times/day orally.

EFFECT: method allows you to reduce the time spent on choosing the most effective therapy regimen, eliminate the empirical stage in its selection, implement individualized patient management tactics, reduce the economic costs of treatment, provided that clinical effectiveness increases.

1 cl, 1 tbl, 4 ex